Cardinal Health FY26: revenue +14.2% to $254.2B, net income +8.7% to $1.71B, EPS +12.1% to $7.23

Filed August 11, 2026 · Period ending June 30, 2026 · Compared to 10-K Aug 12, 2025 · ~1 min read

Key Changes

• high

  $184M goodwill impairment for Navista & ION (oncology MSO) and $122M write-down of Outcomes equity interest reduced GAAP earnings; net impact $0.58/share.

  MD&A: Goodwill impairment; Notes: Outcomes impairment verify on EDGAR →
• high

  Acquired Solaris Health (urology MSO, 750+ providers, 14 states) for $1.9B cash plus $500M equity units to physicians/management; funded with $1.0B new debt and cash.

  MD&A: Solaris acquisition verify on EDGAR →
• high

  Beyond IEEPA, ongoing tariff costs under multiple authorities (Sections 122, 232, 301, 308) not fully offset by price increases; generic pharma may face 100%–200% tariffs in 2028–2029.

  MD&A: Tariffs verify on EDGAR →